Results 61 to 70 of about 209,011 (190)

Cardio-metabolic effectsof HIV protease inhibitors (lopinavir/ritonavir).

PLoS ONE, 2013
Although antiretroviral treatment decreases HIV-AIDS morbidity/mortality, long-term side effects may include the onset of insulin resistance and cardiovascular diseases.
Kathleen M S E Reyskens, Tarryn-Lee Fisher, Jonathan C Schisler, Wendi G O'Connor, Arlin B Rogers, Monte S Willis, Cynthia Planesse, Florence Boyer, Philippe Rondeau, Emmanuel Bourdon, M Faadiel Essop   +10 more
doaj   +1 more source

Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs

Molecules, 2019
HIV protease inhibitors against the viral protease are often hampered by drug resistance mutations in protease and in the viral substrate Gag. To overcome this drug resistance and inhibit viral maturation, targeting Gag alongside protease rather than ...
Chinh Tran-To Su, Darius Wen-Shuo Koh, Samuel Ken-En Gan   +2 more
doaj   +1 more source

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

Pharmacogenetics & Genomics, 2010
Objective OATP1B1 and OATP1B3 are major hepatic drug transporters whilst OATP1A2 is mainly located in the brain but is also located in liver and several other organs.
R. Hartkoorn, W. Kwan, V. Shallcross, Ammara Chaikan, N. Liptrott, D. Egan, Enrique Salcedo Sora, Chloe E. James, S. Gibbons, P. Bray, D. Back, S. Khoo, A. Owen   +12 more
semanticscholar   +1 more source

Discovery of Novel HIV Protease Inhibitors Using Modern Computational Techniques. [PDF]

Int J Mol Sci, 2022
Okafor SN, Angsantikul P, Ahmed H.
europepmc   +1 more source

Adaptive inhibitors of the HIV-1 protease

Progress in Biophysics and Molecular Biology, 2005
A significant obstacle to the efficacy of drugs directed against viral targets is the presence of amino acid polymorphisms in the targeted molecules. Amino acid polymorphisms may occur naturally due to the existence of variations within and between viral strains or as the result of mutations associated with drug resistance.
Hiroyasu, Ohtaka, Ernesto, Freire
openaire   +2 more sources

Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study. [PDF]

Curr Issues Mol Biol, 2022
Fenley JC, de Barros PP, Carmo PHFD, Garcia MT, Rossoni RD, Junqueira JC.   +5 more
europepmc   +1 more source

Evaluation of Platelet Activation by HIV Protease Inhibitors - The HIV-PLA II Study. [PDF]

HIV AIDS (Auckl), 2021
Kann G, Owasil J, Kuczka K, Haberl A, Wolf T, Khaykin P, Harder S, Stephan C, von Hentig N.   +8 more
europepmc   +1 more source

Suspected bradycardia due to interactions between HIV protease inhibitors and lidocaine: a case report. [PDF]

J Dent Anesth Pain Med, 2021
Hamaya E, Kamekura N, Fujisawa T.
europepmc   +1 more source

HIV Protease Inhibitors and Insulin Sensitivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

Front Pharmacol, 2021
Kajogoo VD, Gorret Atim M, Amare D, Geleta M, Muchie Y, Tesfahunei HA, Olomi W, Acam J, Manyazewal T.   +8 more
europepmc   +1 more source

HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect. [PDF]

Antiviral Res, 2022
Foo CS, Abdelnabi R, Kaptein SJF, Zhang X, Ter Horst S, Mols R, Delang L, Rocha-Pereira J, Coelmont L, Leyssen P, Dallmeier K, Vergote V, Heylen E, Vangeel L, Chatterjee AK, Annaert PP, Augustijns PF, De Jonghe S, Jochmans D, Gouwy M, Cambier S, Vandooren J, Proost P, van Laer C, Weynand B, Neyts J.   +25 more
europepmc   +1 more source